Challenges in Standardizing Histologic Endpoints in MASH Cirrhosis Trials

Last week, a quiet but seismic shift rippled through the medical research community—and if you live in Austin, it might already be changing the way your doctor thinks about liver disease. A new review has exposed a critical flaw in how clinical trials for MASH cirrhosis (metabolic dysfunction-associated steatohepatitis, the advanced form of fatty liver disease) measure success. The problem? No two studies seem to agree on what “success” even looks like. For a city where over 30% of adults are estimated to have some form of fatty liver disease—mirroring national trends—this inconsistency isn’t just academic. It’s personal.

Imagine standing at the intersection of Congress Avenue and 6th Street, where the energy of live music venues collides with the quiet urgency of nearby medical centers like Dell Seton Medical Center. Inside those buildings, researchers and clinicians are grappling with a question that could redefine how Austinites with cirrhosis are treated: If the goalposts preserve moving, how can patients and doctors trust that a new drug will actually work?

The Hidden Crisis in MASH Cirrhosis Trials

The review, which scrutinized dozens of recent MASH cirrhosis trials, found that histologic endpoints—the microscopic changes in liver tissue used to determine whether a drug is effective—are alarmingly inconsistent. Some studies focus on reducing liver fibrosis (scarring), whereas others prioritize inflammation or ballooning degeneration of liver cells. A few even apply composite scores that blend multiple factors, but with no standardized formula. This lack of uniformity isn’t just a technical hiccup; it’s a roadblock to progress.

Consider the stakes. MASH cirrhosis is the fastest-growing cause of liver transplants in the U.S., and Texas is no exception. At the Texas Liver Institute in San Antonio, just a short drive from Austin, clinicians have seen firsthand how the disease disproportionately affects Hispanic communities—a demographic that makes up nearly 34% of Austin’s population. When trial endpoints vary wildly, it becomes nearly impossible to compare results across studies, let alone translate them into real-world treatments. A drug that shows promise in one trial might fail in another simply because the two studies measured different things.

This isn’t a new problem. The review highlights past failures, like the phase III trials for selonsertib and simtuzumab, where histology-based endpoints failed to demonstrate clear treatment benefits. These setbacks weren’t just scientific disappointments; they were missed opportunities for patients who had few other options. For Austinites relying on clinical trials at places like Ascension Seton or Baylor Scott & White, the message is clear: The system designed to protect and heal them is built on shaky ground.

Why Austin Should Care

Austin’s health landscape is uniquely positioned to perceive the ripple effects of this inconsistency. The city is a hub for biotech innovation, with startups and research institutions like the University of Texas at Austin’s Dell Medical School driving forward-thinking approaches to chronic disease. But innovation requires clarity—and right now, the lack of standardized endpoints is muddying the waters.

Take, for example, the city’s growing focus on health equity. Austin Public Health has repeatedly flagged liver disease as a priority area, particularly for communities of color who face higher risks due to socioeconomic factors and limited access to care. If clinical trials can’t agree on how to measure success, how can local health initiatives tailor interventions that actually work? The answer, for now, is that they can’t—not with the precision needed to make a real difference.

Then there’s the economic angle. Austin’s booming tech sector attracts a workforce that, statistically, is at higher risk for lifestyle-related conditions like MASH. Employers and insurers are already grappling with the rising costs of chronic disease management. Unreliable trial data only compounds the problem, making it harder to justify coverage for new treatments or invest in preventive care programs. For a city where the cost of living is already a hot-button issue, this could translate into higher premiums or fewer options for those who need them most.

The Human Cost of Inconsistency

Behind the data are real people—like the patients at CommUnityCare Health Centers, where primary care doctors are often the first line of defense against liver disease. For them, the stakes are immediate. A patient with early-stage MASH might be told to monitor their condition with lifestyle changes, but without reliable trial data, doctors can’t confidently recommend emerging therapies. Meanwhile, those with advanced cirrhosis are left in limbo, waiting for treatments that may never materialize because the science couldn’t prove their worth.

This uncertainty also fuels mistrust. Austin’s diverse communities, from the historic Black neighborhoods of East Austin to the growing Asian American enclaves in North Austin, have long navigated healthcare disparities. When trials produce inconsistent results, it’s not just a scientific issue—it’s a trust issue. Patients who’ve been let down by the system before are less likely to participate in future trials, creating a vicious cycle that stalls progress for everyone.

What’s Next? The Push for Standardization

The great news is that the medical community isn’t sitting idle. The review calls for a collaborative effort to establish uniform histologic endpoints, a move that could harmonize trials and accelerate drug development. Organizations like the American Association for the Study of Liver Diseases (AASLD) and the Food and Drug Administration (FDA) are already weighing in, with the FDA recently releasing draft guidance on MASH trial design. For Austin, this could mean a future where local research institutions play a leading role in shaping these standards.

Dell Medical School, for instance, has been at the forefront of integrating community voices into clinical research. Their work with underserved populations could provide valuable insights into how endpoints should be designed to reflect real-world needs. Similarly, the Texas Liver Foundation, based in Austin, has been advocating for better liver disease education, and resources. Their efforts could help bridge the gap between trial data and patient outcomes.

But standardization alone won’t solve everything. The review also highlights the limitations of liver biopsies—the gold standard for assessing histologic endpoints. Biopsies are invasive, expensive, and prone to sampling errors. For a city like Austin, where healthcare access is already uneven, relying on biopsies could exacerbate disparities. This has led some researchers to explore non-invasive alternatives, like blood tests or imaging techniques, which could democratize access to trial participation and monitoring.

Given My Background in Public Health, If This Trend Impacts You in Austin, Here Are the Three Types of Local Professionals You Need

Navigating the complexities of MASH cirrhosis and clinical trials can feel overwhelming, especially when the science itself is in flux. But Austin is home to a network of experts who can help you make sense of it all. Whether you’re a patient, a caregiver, or simply someone concerned about liver health, here’s who Try to grasp—and what to look for when seeking their help.

Hepatology Specialists with Clinical Trial Experience

These are the liver disease experts who not only treat patients but also contribute to research. In Austin, you’ll find them at major medical centers like Dell Seton Medical Center or Ascension Seton, as well as in private practices affiliated with research institutions.

What to look for:

• Board certification in gastroenterology or hepatology, with a focus on fatty liver disease.
• Affiliation with ongoing clinical trials, particularly those exploring new MASH therapies. Request if they’ve participated in trials that used standardized endpoints—this indicates they’re up-to-date on the latest debates in the field.
• Experience working with diverse patient populations. Austin’s demographic diversity means your specialist should understand how liver disease manifests across different ethnic and socioeconomic groups.
• A patient-centered approach. Look for someone who takes the time to explain trial results in plain language and helps you weigh the risks and benefits of participation.

Health Policy and Advocacy Experts

These professionals work behind the scenes to shape the policies and standards that govern clinical trials. In Austin, they’re often found at nonprofits, research institutions, or government agencies like Austin Public Health.

What to look for:

• A background in public health, health policy, or epidemiology, with a focus on chronic disease or health equity.
• Experience advocating for standardized endpoints in clinical trials. Ask if they’ve worked with organizations like the AASLD or the FDA on MASH-related initiatives.
• Knowledge of local health disparities. Austin’s unique demographic and socioeconomic landscape means your advocate should understand how trial inconsistencies might disproportionately affect certain communities.
• A track record of community engagement. The best advocates don’t just work in offices—they partner with local organizations, like the Texas Liver Foundation, to ensure patient voices are heard.

Integrative and Functional Medicine Practitioners

While clinical trials focus on drug development, integrative practitioners take a holistic approach to liver health. In Austin, where wellness culture is thriving, these providers can complement traditional medical care by addressing lifestyle factors that contribute to MASH.

What to look for:

• Credentials in functional medicine, nutrition, or integrative health, with a focus on metabolic or liver health. Look for certifications from organizations like the Institute for Functional Medicine.
• Experience working alongside hepatologists or gastroenterologists. The best integrative practitioners don’t operate in silos—they collaborate with your medical team to ensure a cohesive treatment plan.
• A data-driven approach. Ask how they stay informed about the latest MASH research, including the debates around trial endpoints. They should be able to translate this knowledge into practical advice for diet, exercise, and stress management.
• Cultural competency. Austin’s diverse communities have unique dietary and lifestyle traditions. Your practitioner should respect and incorporate these into your care plan.

Finding the right professional can feel like searching for a needle in a haystack, but Austin’s tight-knit healthcare community makes it easier. Start by asking your primary care doctor for referrals, or reach out to local organizations like the Texas Liver Foundation for guidance. And remember: The goal isn’t just to find an expert—it’s to find someone who understands your unique needs and can help you navigate a system that’s still finding its footing.

Ready to find trusted professionals? Browse our complete directory of top-rated MASH and liver health experts in the Austin area today.